Company / PP&E (Net)
Decoy Therapeutics Inc. PP&E (Net) History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$7.9K
FY2021
5-year range
$7.9K / $74.5K
FY2017-FY2021
Trend
-65.2%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 5 consecutive years, from $556,315 in FY2016 to $7,880 in FY2021.
Based on SEC 10-K filings.
$7,880 in FY2021 with a 5-year CAGR of -57.3%.
Declined from $25,016 to $7,880 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -52.7%
- 5-Year CAGR
- -57.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Decoy Therapeutics Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -57.3%, indicating a declining trend.
- In FY2021, pp&e (net) decreased 65.2% year-over-year.
- Peak pp&e (net) was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | $7.9K | -65.2% |
| FY2020 | $22.6K | -9.5% |
| FY2019 | $25.0K | -66.4% |
| FY2018 | $74.5K | -77.5% |
| FY2017 | $331.0K | -40.5% |
| FY2016 | $556.3K | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026